CrossrefInfokarte
Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study
Breast Cancer · 2025-03 · 32 (2) · 329-336
DOI: 10.1007/s12282-024-01657-4 ↗Abstract
Kein Abstract verfügbar.
EUVIMED